
EPoC Science accelerates neurology drug development with AI-driven digital measures. It applies AI and digital measures to boost statistical power in Phase 2 efficacy trials, focusing on rare diseases like Multiple System Atrophy. The company operates as a biotech drug developer partnering with pharmaceutical companies for efficacy proof-of-concept studies. By combining AI, digital biomarkers, and adaptive trial concepts, it targets reduced trial costs and faster data generation for the pharma industry.

EPoC Science accelerates neurology drug development with AI-driven digital measures. It applies AI and digital measures to boost statistical power in Phase 2 efficacy trials, focusing on rare diseases like Multiple System Atrophy. The company operates as a biotech drug developer partnering with pharmaceutical companies for efficacy proof-of-concept studies. By combining AI, digital biomarkers, and adaptive trial concepts, it targets reduced trial costs and faster data generation for the pharma industry.